Patents by Inventor Zhiya Yu
Zhiya Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220389093Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: August 4, 2022Publication date: December 8, 2022Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Patent number: 11440956Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: September 27, 2019Date of Patent: September 13, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Publication number: 20220088164Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: November 24, 2021Publication date: March 24, 2022Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Patent number: 11207394Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: November 24, 2015Date of Patent: December 28, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Publication number: 20200317807Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding—transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Patent number: 10689456Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: April 9, 2015Date of Patent: June 23, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Publication number: 20200102383Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 27, 2019Publication date: April 2, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Patent number: 10450372Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the disclosure are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: November 12, 2015Date of Patent: October 22, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Publication number: 20180244768Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the disclosure are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: November 12, 2015Publication date: August 30, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
-
Publication number: 20180208671Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intra-cellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: April 9, 2015Publication date: July 26, 2018Applicant: The United States of America, as Represented by Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Publication number: 20170304421Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for an HLA-A11-restricted epitope of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) (KRAS7-16), Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS), or Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: November 24, 2015Publication date: October 26, 2017Applicant: The United States of America, as represented by the Secretary, Dep. of Health and Human ServicesInventors: Qiong J. WANG, Zhiya YU, James C. YANG
-
Patent number: 9522948Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: December 13, 2013Date of Patent: December 20, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20140219978Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: December 13, 2013Publication date: August 7, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8613932Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: May 30, 2012Date of Patent: December 24, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20120230962Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: May 30, 2012Publication date: September 13, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8216565Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: January 11, 2008Date of Patent: July 10, 2012Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20100015113Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: January 11, 2008Publication date: January 21, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg